Clinical trials: T-Cell Lymphocytic Leukemia
B-cell Acute Lymphoblastic Leukemia
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).
- Trial name
- NCT04534634
- Testing
- IFN-α combined with CAR-T cell therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Acute Lymphoblastic
CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
This is a single center, single arm, open-label phase 2 study to determine the efficacy of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains…
- Trial name
- NCT02935543
- Testing
- CART 19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Pennsylvania
Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukaemia
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia.
- Trial name
- NCT07623655
- Volunteers
- 107 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloproliferative Disorders, Leukemia
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
RATIONALE: EMD 121974 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have locally advanced or metastatic cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004258
- Testing
- cilengitide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients…
- Conditions
- Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT03501576
- Testing
- Inactivated Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Emory University
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory…
- Trial name
- NCT06173518
- Testing
- AUTO1
- Where
- 14 sites in United States, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- Autolus Limited
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
- Trial name
- Phase I/II (NCT06880913)
- Testing
- Nanobody-Based CD19/CD22 Tandem Dual CAR-T
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
B-cell Acute Lymphocytic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy.
- Trial name
- NCT03263208
- Testing
- Cyclophosphamide, Fludarabine, CD19 CAR-T
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Leukemia, Myelodysplastic Syndromes
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00077558
- Testing
- fludarabine phosphate, triapine
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
This phase I trial is studying the side effects and best dose of methoxyamine when given together with fludarabine phosphate in treating patients with relapsed or refractory hematologic malignancies.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01658319
- Testing
- fludarabine phosphate, methoxyamine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
Anxiety Disorder, Cancer Survivor
Quality of Life in Younger Leukemia and Lymphoma Survivors
RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment.
- Conditions
- Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia
- Trial name
- NCT00956475
- Testing
- telephone-based intervention, questionnaire administration, assessment of therapy complications
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Case Comprehensive Cancer Center
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
Non-Hodgkin CD20 + Indolent Lymphoma (iNHL) and Chronic Lymphatic Leukemia (CLL) are the most frequent neoplasms of B lymphocytes.
- Trial name
- BET2017 (NCT03823365)
- Testing
- Blinatumomab Expanded T-cells (BET)
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03733249
- Testing
- Rimiducid, rivogenlecleucel
- Where
- Italy
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric…
- Trial name
- NCT06027957
- Testing
- anti-CD19 CAR T-cells
- Where
- Vietnam
- Volunteers
- 18 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well sapanisertib works in treating patients with acute lymphoblastic leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory).
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02484430
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
SJCAR19 is a research study seeking to evaluate the use of chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of pediatric, adolescent and young adult patients with relapsed or…
- Trial name
- NCT03573700
- Testing
- Cyclophosphamide, Fludarabine, Mesna
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Adult T-Cell Leukemia/Lymphoma (ATLL)
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
This study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell…
- Trial name
- NCT07075328
- Testing
- Drug:5-ALA, Device:Photodynamic system
- Where
- 5 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Otsuka Medical Devices Co., Ltd. Japan
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD…
- Trial name
- NCT05626400
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.